# Inhibikase Therapeutics, Inc. (IKT)

> Source: Nexqual · https://nexqual.com/IKT · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Inhibikase Therapeutics, Inc. (IKT), nexqual.com/IKT" · informational, not investment advice.

**Price:** USD 1.83 (+1.67% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 1.8 · day 1.8–1.87 · 52w 1.33–2.61 · market cap $255M · NCM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (10 analysts), mean target USD 5.55 (range 1.5–8).
- Total return with dividends: 1Y +21.2% vs S&P 500 +18.1%; 5Y -84.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-13, EPS estimate USD -0.13, revenue estimate $0K.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 10 analysts; mean target USD 5.55 (low 1.5, high 8).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Chardan Capital | Initiated | Neutral | $1.5 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +21.2% | -84.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +21.3% | -30.8% |
| Volatility (annualized) | 61.5% | 88.5% |
| Max drawdown | -30.2% (Sep 2026→Oct 2026) | -93.6% (Nov 2021→Oct 2023) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/IKT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt